Topiramate (brand name Topamax) is the migraine prevention medication most consistently linked to weight loss. In clinical trials, patients taking topiramate for migraines lost an average of 4.8% of their body weight over 26 weeks, and some studies have documented losses of up to 15% to 18% of baseline weight. It’s one of the few migraine preventives that moves the scale downward rather than up, which is why many people specifically ask about it.
How Topiramate Causes Weight Loss
Topiramate was originally developed as an anti-seizure drug, and its weight loss effect was discovered as a side effect during epilepsy trials. The exact mechanism isn’t fully mapped out, but researchers have identified several pathways working together. The drug appears to interfere with how your body stores energy, reducing fat accumulation even without major changes in how much you eat. It also seems to ramp up thermogenesis, the process by which your body burns calories to generate heat, particularly in muscle and a type of fat tissue that specializes in calorie burning.
There’s also a hormonal component. Topiramate influences leptin signaling, the system your brain uses to gauge whether you’ve eaten enough. It appears to boost the activity of appetite-suppressing signals in the hypothalamus, the brain’s hunger control center. On top of that, the drug inhibits an enzyme involved in creating new fat at the cellular level. Many patients also report that food simply tastes different or less appealing while on topiramate, sometimes described as a metallic or flat taste, which naturally reduces how much they eat.
What the Weight Loss Timeline Looks Like
Weight loss from topiramate tends to be gradual and dose-dependent. In a 26-week study of 483 migraine patients, those on doses of 50, 100, or 200 mg daily lost an average of 4.8% of their body weight. People who weigh more at the start generally lose more. The weight continues to come off for as long as you stay on the medication, meaning it’s not a short burst of loss that plateaus quickly. However, it also means that stopping topiramate can lead to regaining weight, since the metabolic effects don’t persist once the drug clears your system.
For migraine prevention specifically, most prescribers start at a low dose and increase gradually to reduce side effects. The typical target dose for migraines (100 mg daily) is lower than what’s used in dedicated weight loss studies, so the amount of weight you lose will likely be moderate rather than dramatic.
Zonisamide as a Second Option
Zonisamide is another anti-seizure medication sometimes used off-label for migraine prevention, and it can also cause weight loss. In a year-long trial of 225 obese adults, those taking 400 mg daily lost an average of 7.3 kg (about 16 pounds), compared to 4.0 kg in the placebo group. That’s roughly 3.3 kg of additional weight loss attributable to the drug. Over half of the patients on the higher dose achieved at least 5% body weight loss, and about a third lost 10% or more.
The catch is that the lower 200 mg dose didn’t perform significantly better than placebo for weight loss, and the higher dose came with a high rate of side effects. Zonisamide isn’t as well-studied for migraine prevention as topiramate, so it’s typically considered when topiramate isn’t tolerated or doesn’t work.
Why This Matters: Most Migraine Drugs Do the Opposite
Weight gain is one of the most common complaints about migraine preventives, which is partly why the question of weight-loss-friendly options comes up so often. In a six-month follow-up study, 86% of patients on pizotifen gained weight (averaging about 4.4 kg), and 60% of those on low-dose amitriptyline gained weight (averaging 3.1 kg). Higher doses of amitriptyline pushed the average gain to 5.4 kg in nearly half of patients. Valproate, another common preventive, caused weight gain in about 25% of patients.
Beta-blockers like propranolol and atenolol fared somewhat better, with only 8% and 20% of patients gaining weight respectively, though when propranolol did cause gain in one patient, it was a substantial 6 kg. Gabapentin was relatively weight-neutral, with only 9% of patients gaining. For people who are already concerned about their weight, this landscape makes topiramate a particularly appealing choice since it’s the only first-line migraine preventive that reliably trends in the other direction.
CGRP Inhibitors Are Weight-Neutral
The newer class of migraine-specific medications, CGRP inhibitors (injections like erenumab, fremanezumab, and galcanezumab, or the infusion eptinezumab), don’t appear to cause meaningful weight changes in either direction. Clinical analysis of eptinezumab in overweight and obese patients found no significant effect on metabolic rate, energy metabolism, or food intake compared to placebo. These drugs target the migraine pathway directly rather than broadly affecting brain chemistry, which is why they tend to have fewer systemic side effects, but it also means they won’t help with weight loss.
If weight loss is a priority alongside migraine control, CGRP inhibitors won’t check that box. But if you’re on a weight-gaining preventive and want to switch to something neutral, they’re worth discussing.
Topiramate’s Side Effects Beyond Weight
Weight loss may sound like a welcome bonus, but topiramate comes with trade-offs that stop some people from staying on it. The most commonly reported issues include tingling or numbness in the hands and feet, difficulty finding words or thinking clearly (sometimes called “brain fog” or jokingly “dopamax”), fatigue, and changes in taste. Carbonated drinks in particular often taste flat or metallic. Some people experience memory difficulties or slowed processing speed, which can be a dealbreaker for those in mentally demanding jobs.
There’s also a risk of kidney stones with long-term use, and the drug is not safe during pregnancy due to a risk of birth defects. These side effects are dose-dependent, meaning they’re more likely and more intense at higher doses. The migraine prevention dose is lower than what’s typically used for weight management, which helps, but cognitive effects can show up even at moderate doses.
The Combination Drug: Phentermine/Topiramate
Topiramate is also a component of a combination weight loss medication that pairs it with phentermine, a stimulant appetite suppressant. This combination is FDA-approved specifically for obesity, not for migraine prevention. While the topiramate component could theoretically help with both conditions, the combination drug hasn’t been studied in migraine trials. If you have both obesity and migraines, it’s a conversation worth having with your provider, but it’s not a standard migraine treatment.